Zantac and Cancer
The generic name for Zantac is ranitidine. Although once used as rocket fuel, it was commonly prescribed to treat acid in the stomach, ulcers, and gastroesophageal reflux disease.
Sanofi-Aventis voluntarily recalled Zantac after independent testing detected substantial amounts of NDMA.
NDMA has been linked to liver cancer, stomach cancer, kidney cancer, and bladder cancer.
National drugstore chains such as Walmart, CVS, and Walgreens pulled Zantac and all other ranitidine medications off their shelves after learning about the test results.
On April 1, 2020, the FDA requested manufacturers to withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately.
History of Zantac and Cancer
1980s: Ranitidine (aka Zantac) is shown to form thousands of ng of NDMA, a suspected carcinogen, in the human stomach. The FDA maximum daily exposure of NDMA is only 96 mg.
2004: National Cancer Institute links antacids and ranitidine to bladder cancer.
2016: A 2016 Stanford University study found that after the ingestion of a single 150 mg tablet of Zantac, healthy patients excreted, on average, over 47,700 nanograms of NDMA in 24 hours.
2019: Valisure shows ranitidine forms millions of ng of NDMA within the human body.
2020: The Federal Drug Administration requests withdrawal of all ranitidine drugs from the market immediately because of the link between Zantac and cancer.
Did You Use Zantac and Have Cancer?
Millions of people have treated chronic stomach ailments by using ranitidine-based medications.
People who used Zantac and other ranitidine-containing medicines are at the greatest risk of developing cancer from the NDMA found in these medications.
Anyone who used Zantac and has received a diagnosis of cancer in the bladder, colon, rectum, esophagus, kidney, liver, lung, pancreas, prostate, or stomach may have a legal cause of action for damages.
Plaintiffs claim that Defendants like Sanofi-Aventis knew about the potential cancer causing problems and failed to inform consumers of the associated risks.
If you or a loved one used Zantac and were diagnosed with these cancer types, please fill out the form for a legal advocate to review your claim.
Claims Available for Zantac
FAILURE TO WARN
Manufacturers failed to warn doctors and patients about the potential risks of elevated exposure to NDMA – despite studies that link it with a higher risk of cancer.
It is important to consider having an attorney review your medical information following an injury associated with Zantac and ranitidine. Get help today from someone who can advocate for your rights.
PAIN & SUFFERING
Drug companies have a responsibility to provide safe products. Patients may receive compensation when these companies breach their duties and expose consumers to getting cancer.
Victims who have been unable to work due to being diagnosed with cancer may qualify for compensation. Don’t let the drug companies get away with putting profits over lives.